Last quarter (Q4 2022), Rhythm Biosciences Ltd.'s total revenue was AU$―, a decrease of ― from previous quarter. In Q4, Rhythm Biosciences Ltd.'s net income was AU$―. See Rhythm Biosciences Ltd.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	-	-	-	-	-
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	-	AU$ 11.25M	AU$ 7.73M	AU$ 4.16M	AU$ 3.71M
Operating Income	-	AU$ -11.25M	AU$ -7.73M	AU$ -4.16M	AU$ -3.71M
Net Non Operating Interest Income Expense	-	AU$ 24.96K	AU$ 12.79K	AU$ 38.47K	AU$ 141.07K
Other Income Expense	-	AU$ 2.43M	AU$ 1.11M	AU$ 100.00K	AU$ 1.03M
Pretax Income	-	AU$ -8.79M	AU$ -6.61M	AU$ -4.02M	AU$ -2.55M
Tax Provision	-	AU$ 0.00	AU$ 0.00	AU$ 0.00	AU$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	-	AU$ -8.79M	AU$ -6.61M	AU$ -4.02M	AU$ -2.55M
Basic EPS	-	AU$ -0.04	AU$ -0.04	AU$ -0.03	AU$ -0.02
Diluted EPS	-	AU$ -0.04	AU$ -0.04	AU$ -0.03	AU$ -0.02
Basic Average Shares	-	AU$ 209.95M	AU$ 185.96M	AU$ 115.45M	AU$ 115.14M
Diluted Average Shares	-	AU$ 209.95M	AU$ 185.96M	AU$ 115.45M	AU$ 115.14M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	-	AU$ -8.79M	AU$ -6.61M	AU$ -4.02M	AU$ -2.55M
Normalized Income	-	AU$ -8.79M	AU$ -6.61M	AU$ -4.02M	AU$ -2.55M
Interest Expense	-	-	AU$ 396.00	AU$ 7.80K	-
EBIT	-	AU$ -11.25M	AU$ -6.61M	AU$ -4.02M	AU$ -3.71M
EBITDA	-	AU$ -11.14M	AU$ -6.47M	AU$ -3.87M	AU$ -3.65M

Currency in AUD

Rhythm Biosciences Ltd. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing